In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kowa Company, Ltd.

https://www.kowa.co.jp/eng/

Latest From Kowa Company, Ltd.

AstraZeneca Buys Into COVID-19 Antibodies From Newly Launched RQ Bio

The big pharma company and its new partner both expect demand to continue for pre-exposure prophylaxis antibody therapies, for COVID-19 and beyond.

Deals Infectious Diseases

Finance Watch: VC Mega-Rounds Are Alive And Well

Private Company Edition: Also, Catalio closed a $381m venture capital fund and OrbiMed’s SEC filings indicate it is in the process of raising $4.75bn across three new funds. Dianthus launched with $100m and Tubulis closed a $63m series B round.

Financing Innovation

Finance Watch: Neuron23 Adds $100m To Take First Drug Into The Clinic

Private Company Edition: Westlake Village BioPartners-founded Neuron23 will take the LRRK2 inhibitor NEU-723 for Parkinson’s disease into human testing before the end of 2022. Also, Celsius raised $83m in fresh VC cash and ITM added another €33m to its recent €25m equity financing.

StartUps and SMEs Financing

Novartis Lays A New Foundation In Prostate Cancer With Second Radioligand Launch

"We have big plans," oncology president Susanne Schaffert said in an interview about launching Pluvicto, its new radioligand therapy for prostate cancer.

Cancer Launches
See All

Company Information

  • Industry
  • Diversified
  • Pharmaceuticals
    • OTC, Consumer
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Implantable Devices
  • Other Names / Subsidiaries
    • ProEthic Pharmaceuticals
UsernamePublicRestriction

Register